氮杂环十二烷 | 294-63-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 氮杂环十二烷
• 英文名称: azacyclododecane
• 英文别名: Azacyclododecan
• CAS: 294-63-3
• 化学式: C₁₁H₂₃N
• 分子量: 169.31
• InChiKey: KFAUAWMNLGGWLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  氮杂环十二烷 、 9,10-dioxo-9,10-dihydroanthracene-2,7-disulfonyl dichloride 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 2,7-bis(azacyclododecan-1-ylsulfonyl)anthracene-9,10-dione
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors

  摘要：

  The Wnt/beta-catenin signaling pathway plays a vital role in cell growth, the regulation, cell development, and the differentiation of normal stem cells. Constitutive activation of the Wnt/beta-catenin signaling pathway is found in many human cancers, and thus, it is an attractive target for anticancer therapy. Specific inhibitors of this pathway have been keenly researched and developed. Cell based screening of compounds library, hit-to-lead optimization, computational and structurebased design strategies resulted in the design and synthesis of a series of anthracene-9,10-dione dioxime series of compounds demonstrated potent inhibition of beta-catenin in vitro (IC50 < 10 nM, 14) and the growth of several cancer cell lines. This article discusses the potential of inhibiting the Wnt/beta-catenin signaling pathway as a therapeutic approach for cancer along with an overview of the development of specific inhibitors.

  DOI：

  10.1021/acs.jmedchem.5b00460
• 作为产物：
  描述：

  环十一酮肟 在 lithium aluminium tetrahydride 、 乙醚 、 硫酸 作用下， 生成 氮杂环十二烷
  参考文献：
  名称：

  Ruzicka et al., Helvetica Chimica Acta, 1949, vol. 32, p. 552

  摘要：

  DOI：

文献信息

• [EN] PYRIDYL-AZA(THIO)XANTHONE SENSITIZER COMPRISING LANTHANIDE(III) ION COMPLEXING COMPOUNDS, THEIR LUMINESCENT LANTHANIDE (III) ION COMPLEXES AND USE THEREOF AS FLUORESCENT LABELS.<br/>[FR] SENSIBILISATEUR PYRIDYL-AZA(THIO)XANTHONE COMPRENANT DES COMPOSÉS COMPLEXANT LES IONS LANTHANIDE(III), LEURS COMPLEXES DES IONS LANTHANIDE(III) LUMINESCENTS ET LEUR UTILISATION COMME MARQUEURS FLUORESCENTS
  申请人：CIS BIO INT

  公开号：WO2010084090A1

  公开（公告）日：2010-07-29

  Lanthanide (III) Ion completing compound comprising: (1) a sensitizer moiety of Formula (I) in which: a is an integer from 1 to 4; b is an integer equal to 1 or 2; c is an integer equal to 1 or 2; (R1)a, (R2)b, (R3)C are the same or different and are chosen from the group consisting of H; alkyl; -COOR4 where R4 is H or an alkyl; aryl; heteroaryl; saturated or unsaturated cyclic hydrocarbon; CF3; CN; a halogen atom; L-Rg; L-Sc; or two consecutive R3, two consecutive R2 or two consecutive R1 groups together form an aryl or a heteroaryl group or a saturated or unsaturated cyclic hydrocarbon group; where L is a linker, Rg is a reactive group and Sc is a conjugated substance; X1 and X2 are the same or different and are O or S; A is either a direct bond or a divalent group chosen from -CH2- or -(CH2)2-, said moiety being covalentiy attached to (2) a lanthanide (in) ion chelating moiety through A. The above compounds are used in the preparation of luminescent lanthanide (III) ion complexes which are used as fluorescent labels.

  镧系（III）离子配合物包括：（1）式（I）中的感光团，其中：a是1到4之间的整数；b是等于1或2的整数；c是等于1或2的整数；（R1）^a，（R2）^b，（R3）^c相同或不同，并选自H；烷基；-COOR4，其中R4为H或烷基；芳基；杂芳基；饱和或不饱和环烃；CF3；CN；卤原子；L-Rg；L-Sc；或两个连续的R3，两个连续的R2或两个连续的R1组成芳基或杂芳基或饱和或不饱和环烃基；其中L是连接物，Rg是反应性基团，Sc是共轭物质；X1和X2相同或不同，为O或S；A是直接键或从-CH2-或-( )2-中选择的二价基团，所述团通过A与（2）中的镧系（III）离子螯合团结合。上述化合物用于制备发光的镧系（III）离子配合物，用作荧光标记剂。
• [EN] WNT PATHWAY ANTAGONISTS<br/>[FR] ANTAGONISTES DE LA VOIE WNT
  申请人：SIENA BIOTECH SPA

  公开号：WO2011042145A1

  公开（公告）日：2011-04-14

  The present invention relates to known and novel compounds of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) have inhibitory effect on the Wnt pathway and are therefore useful in the preparation of a medicament, in particular for the treatment of cancer.

  本发明涉及如下所述的已知和新颖的化合物（I）的公式及其药物组成。公式（I）的化合物对Wnt途径具有抑制作用，因此在制备药物方面特别适用于治疗癌症。
• [EN] GRANZYME B DIRECTED IMAGING AND THERAPY<br/>[FR] IMAGERIE DU GRANZYME B ET THÉRAPIE DIRIGÉES CONTRE LE GRANZYME B
  申请人：CYTOSITE BIOPHARMA INC

  公开号：WO2019160916A1

  公开（公告）日：2019-08-22

  Provided herein are heterocyclic compounds useful for imaging Granzyme B. Methods of imaging Granzyme B, combination therapies, and kits comprising the Granzyme B imaging agents are also provided.

  本文提供了用于成像Granzyme B的杂环化合物。还提供了成像Granzyme B的方法、联合疗法以及包含Granzyme B成像试剂的试剂盒。
• Chemical exchange saturation transfer contrast agents
  申请人：Caravan D. Peter

  公开号：US20060275217A1

  公开（公告）日：2006-12-07

  Chelating ligands and metal chelates useful as CEST MR contrast agents are disclosed. The CEST agents can be used to evaluate blood volume changes in the heart and brain.

  螯合配体和金属螯合物作为CEST磁共振对比剂是有用的。CEST对比剂可用于评估心脏和大脑的血容量变化。
• [EN] CELL-PERMEABLE PROBES FOR IDENTIFICATION AND IMAGING OF SIALIDASES<br/>[FR] SONDES PERMÉABLES AUX CELLULES POUR L'IDENTIFICATION ET L'IMAGERIE DE SIALIDASES
  申请人：ACADEMIA SINICA

  公开号：WO2014031498A1

  公开（公告）日：2014-02-27

  Provided herein are novel irreversible sialidase inhibitors. These compounds can be conjugated with a detectable tagging moiety such as azide-annexed biotin via CuAAC for isolation and identification of sialidases. The provided compounds and the corresponding detectable conjugates are useful for detecting sialidase-containing pathogens and imaging in situ sialidase activities under physiological conditions.

  提供了一种新型的不可逆唾液酸酶抑制剂。这些化合物可以通过点击化学（CuAAC）与可检测的标记基团（如叠氮基连在生物素上）进行偶联，用于分离和识别唾液酸酶。所提供的化合物及相应的可检测偶联物可用于检测含有唾液酸酶的病原体，以及在生理条件下对唾液酸酶活性进行成像。